Increase in the concentration of plasma L-cysteine is closely associated with defective insulin secretion from pancreatic β-cells, which results in type 2 diabetes (T2D). In this study, we investigated the effects of prolonged L-cysteine treatment on glucosestimulated insulin secretion (GSIS) from mouse insulinoma 6 (MIN6) cells and from mouse pancreatic islets, and found that the treatment reversibly inhibited glucose-induced ATP production and resulting GSIS without affecting proinsulin and insulin synthesis. Comprehensive metabolic analyses using capillary electrophoresis time-of-flight mass spectrometry showed that prolonged L-cysteine treatment decreased the levels of pyruvate and its downstream metabolites. In addition, methyl pyruvate, a membrane-permeable form of pyruvate, rescued L-cysteine-induced inhibition of GSIS. Based on these results, we found that both in vitro and in MIN6 cells, L-cysteine specifically inhibited the activity of pyruvate kinase muscle isoform 2 (PKM2), an isoform of pyruvate kinases that catalyze the conversion of phosphoenolpyruvate to pyruvate. L-cysteine also induced PKM2 subunit dissociation (tetramers to dimers/monomers) in cells, which resulted in impaired glucose-induced ATP production for GSIS. DASA-10 (NCGC00181061, a substituted N,N′-diarylsulfonamide), a specific activator for PKM2, restored the tetramer formation and the activity of PKM2, glucoseinduced ATP production, and biphasic insulin secretion in L-cysteinetreated cells. Collectively, our results demonstrate that impaired insulin secretion due to exposure to L-cysteine resulted from its direct binding and inactivation of PKM2 and suggest that PKM2 is a potential therapeutic target for T2D.
Increase in the concentration of plasma L-cysteine is closely associated with defective insulin secretion from pancreatic β-cells, which results in type 2 diabetes (T2D). In this study, we investigated the effects of prolonged L-cysteine treatment on glucosestimulated insulin secretion (GSIS) from mouse insulinoma 6 (MIN6) cells and from mouse pancreatic islets, and found that the treatment reversibly inhibited glucose-induced ATP production and resulting GSIS without affecting proinsulin and insulin synthesis. Comprehensive metabolic analyses using capillary electrophoresis time-of-flight mass spectrometry showed that prolonged L-cysteine treatment decreased the levels of pyruvate and its downstream metabolites. In addition, methyl pyruvate, a membrane-permeable form of pyruvate, rescued L-cysteine-induced inhibition of GSIS. Based on these results, we found that both in vitro and in MIN6 cells, L-cysteine specifically inhibited the activity of pyruvate kinase muscle isoform 2 (PKM2), an isoform of pyruvate kinases that catalyze the conversion of phosphoenolpyruvate to pyruvate. L-cysteine also induced PKM2 subunit dissociation (tetramers to dimers/monomers) in cells, which resulted in impaired glucose-induced ATP production for GSIS. DASA-10 (NCGC00181061, a substituted N,N′-diarylsulfonamide), a specific activator for PKM2, restored the tetramer formation and the activity of PKM2, glucoseinduced ATP production, and biphasic insulin secretion in L-cysteinetreated cells. Collectively, our results demonstrate that impaired insulin secretion due to exposure to L-cysteine resulted from its direct binding and inactivation of PKM2 and suggest that PKM2 is a potential therapeutic target for T2D.
A metabolite, L-cysteine, is found in blood plasma, and its concentration is closely associated with an increase in fat mass and the body-mass index. These values are used as an index of obesity (1, 2), which is a major risk factor for type 2 diabetes (T2D) (3) . The relationship between L-cysteine and diabetes has attracted attention because there is increasing evidence for a positive correlation between increases in plasma L-cysteine concentrations and the development and progression of diabetes. For example, increased plasma L-cysteine concentrations were associated with T2D in African American women (4) , renal insufficiency [reduced glomerular filtration rate (GFR)] in T2D patients (5) , obstructive sleep apnea [a risk factor for diabetes (6, 7) ], and insulin resistance among Europeans (8) .
Reduced insulin secretion from pancreatic β-cells is the major cause of T2D (9, 10) . Many investigators have studied the molecular mechanisms of glucose-stimulated insulin secretion (GSIS), which have been elucidated in detail. Elevated extracellular glucose concentration results in the enhancement of ATP production, an increased ATP/ADP ratio, the closure of ATP-sensitive K channels (K ATP channels), and depolarization (11) . The resulting activation of voltage-dependent Ca 2+ channels (VDCCs) induces an influx of calcium ions and elevated intracellular Ca 2+ concentrations, which triggers insulin secretion (11) . Perifusion experiments have shown that insulin secretion could be categorized into two phases. The first phase involves a sharp increase in insulin secretion within ∼5 min, followed by a second phase, during which moderate insulin secretion lasts for hours (9, 12) . A loss of the GSIS first phase is closely associated with the future development of T2D (9, 13, 14) .
Many recent studies have reported that L-cysteine is involved in GSIS. In mouse pancreatic islets and mouse insulinoma 6 (MIN6) cells, L-cysteine treatment decreased both intracellular ATP levels and insulin secretion (15) . Ammon et al. also reported that the total amount and GSIS second phase were specifically inhibited by L-cysteine for rat pancreatic islets (16) . Several groups showed that an increase in the H 2 S moiety, which is generated from L-cysteine in cells (17) , was one possible cause for L-cysteine-induced impairment of GSIS by inhibiting K ATP channels and VDCCs (18) (19) (20) . However, opposite results were Significance There is increasing evidence for a positive correlation between increases in plasma L-cysteine concentrations and the development and progression of type 2 diabetes (T2D) caused by obesity. Here, we show that prolonged treatment of mouse insulinoma 6 (MIN6) cells and mouse pancreatic islets with L-cysteine inhibited glucose-stimulated insulin secretion (GSIS). L-cysteine reversibly inactivated pyruvate kinase muscle isoform 2 (PKM2), an isoform of the rate-limiting enzyme pyruvate kinase in glycolysis, by inducing PKM2 subunit dissociation (tetramers to dimers/monomers), which resulted in impairment of glucoseinduced ATP production and subsequent GSIS. Our findings in this work will raise caution about using a variety of L-cysteine containing supplements to diabetic patients and shed a light on a previously unidentified physiological role of L-cysteine and PKM2.
reported in that L-cysteine increased the amount of total and first-phase insulin secretion by rat pancreatic islets (16, 21) . Thus, the effects of L-cysteine on GSIS remain controversial. It should be noted that most of these studies on the effects of L-cysteine on GSIS were performed using experimental conditions in which insulin-secreting cells were only transiently exposed (∼1 h) to a high glucose solution that contained L-cysteine. However, in obese or T2D patients, insulin-secreting cells can be exposed to plasma that contains L-cysteine for prolonged periods of time; thus, continuous exposure to an L-cysteine-containing solution is necessary to investigate the precise effects of L-cysteine on GSIS in insulin-secreting cells.
In this study, we found that L-cysteine treatment of statically incubated or perifused MIN6 cells and mouse pancreatic islets resulted in reversibly inhibiting GSIS. A comprehensive analysis of charged metabolites in L-cysteine-treated MIN6 cells by capillary electrophoresis time-of-flight mass spectrometry (CE-TOF-MS) showed significant accumulations of L-cysteine and, concomitantly, decreased levels of pyruvate and its downstream metabolites in the tricarboxylic acid (TCA) cycle in these cells. Biochemical experiments for pyruvate kinase activity in vitro and in MIN6 cells showed that L-cysteine specifically inhibited the activity of pyruvate kinase muscle isoform 2 (PKM2), an isoform of major pyruvate kinases in pancreatic islets (22) that catalyzes the glycolytic conversion of phosphoenolpyruvate (PEP) to pyruvate. PKM2 inactivation resulted from L-cysteine-induced subunit dissociation (tetramers to dimers/monomers) and inhibited glucose-induced ATP production for GSIS in MIN6 cells. Impaired GSIS due to L-cysteine was restored by treatment with methyl pyruvate, a membrane-permeable form of pyruvate, or DASA-10 (NCGC00181061, a substituted N,N′-diarylsulfonamide), a specific activator of PKM2 (23) . Thus, we concluded that reduced PKM2 activity due to L-cysteine inhibited ATP production and subsequently inhibited GSIS by insulin-secreting cells.
Results
Prolonged L-Cysteine Treatment Inhibits GSIS. We first examined the effects of prolonged L-cysteine treatment on GSIS by MIN6 cells. The concentrations of L-cysteine in the media or assay buffers used in these experiments were determined with reference to previous reports (1, 7, 15) . After incubating MIN6 cells in 25 mM glucose-containing medium (25G-M) that included 0, 1, or 2 mM L-cysteine for 24 h, the cells were preincubated with 3 mM glucose-containing Krebs-Ringer bicarbonate buffer (3G-KRBB) for 1 h and then used for GSIS assays for 30 min with 25 mM glucose-containing KRBB (25G-KRBB) in the presence or absence of L-cysteine (Fig. 1A) . GSIS was reduced to ∼25% of control levels (without L-cysteine) in the presence of 1 or 2 mM L-cysteine (Fig. 1A) . In contrast, transient treatment with 1 or 2 mM L-cysteine in 25G-KRBB resulted in normal GSIS similar to that of control cells (Fig. 1A, "transient") .
Next, we measured the total amounts of proinsulin and insulin in cells after preculture in 25G-M that contained 0, 1, or 2 mM L-cysteine for 24 h. This analysis showed that the total amounts of these proteins in L-cysteine-treated cells were not very different from those in untreated cells (Fig. S1 A and B) . This result indicated that L-cysteine treatment had no effect on proinsulin and insulin synthesis in MIN6 cells; rather, L-cysteine effects were exerted on postbiosynthetic pathways, such as insulin secretion.
Prolonged L-Cysteine Treatment Inhibits Glucose-Induced ATP Production and Ca 2+ Influx. Glucose-induced ATP production, followed by a Ca 2+ influx into cells, is essential for normal GSIS (11) . For example, for rat islets, intracellular ATP concentrations increased transiently to nearly 1.2 times the normal level within 5 min after high-glucose stimulation and then returned to normal levels within 30 min (24) . This transient increase in intracellular ATP is due to glucose-induced ATP production and is essential for GSIS. Thus, using the same conditions as those seen in Fig.  1A , we determined intracellular ATP levels in MIN6 cells after 25 mM glucose stimulation using a luciferase/luciferin assay (Materials and Methods). As shown in Fig. 1B , compared with nonstimulated levels, the increase in intracellular ATP after high-glucose stimulation was nearly 210% at 5 min and 170% at 30 min. In contrast, in cells after prolonged treatment with 1 or 2 mM L-cysteine, this transient increase in ATP production was inhibited, and the increases were <100% of nonstimulated levels at both 5 and 30 min after high-glucose stimulation (Fig. 1B) .
A lack of glucose-induced ATP production due to L-cysteine might also perturb K ATP channels in the plasma membrane and consequently inhibit a Ca 2+ influx into L-cysteine-treated MIN6 Table S1 for experimental details). Results are means ± SEs of the means.
NS P > 0.05, *P < 0.05, ***P < 0.001. cells. To test this hypothesis, we assessed the effects of L-cysteine on glucose-induced Ca 2+ influx in MIN6 cells using fluorescence microscopy. In Fluo4-loaded cells without L-cysteine treatment, there was a sharp increase in fluorescence intensity after glucose exposure (Fig. S2A) . In contrast, Fluo4 fluorescence was not increased in cells treated with L-cysteine, which suggested nearly complete inhibition of glucose-induced Ca 2+ influx due to L-cysteine treatment (Fig. S2A) . Closure of K ATP channels and opening of VDCCs play a crucial role in Ca 2+ influx that triggers GSIS upon high-glucose stimulation (11) . KCl, a membrane depolarizer, and maitotoxin, a calcium channel opener, induce Ca 2+ influx and subsequent insulin secretion (11, (25) (26) (27) (28) . Thus, we examined the effects of L-cysteine treatment on KCl-and maitotoxin-induced insulin secretion by MIN6 cells; this treatment had little effect on insulin secretion ( Fig. 1 C and D) . Furthermore, whereas H 2 S generation by L-cysteine treatment was reported to inhibit K ATP channels and VDCCs and the subsequent insulin secretion, we found that prolonged L-cysteine treatment had no significant effect on H 2 S production in MIN6 cells (Fig. S2B) . These results showed that prolonged L-cysteine treatment was restricted to some components of the insulin secretion machinery upstream of Ca 2+ -channel activation (such as glucose uptake and ATP production). (11) . We investigated for any metabolic alterations in MIN6 cells after prolonged L-cysteine treatment. After incubating MIN6 cells in 25G-M that contained 0, 1, or 2 mM L-cysteine for 24 h, the steady-state metabolite levels in these cells were analyzed by CE-TOF-MS. As expected, compared with the levels in untreated cells, L-cysteine concentrations were significantly increased by 4.8 and 7.6 times in cells treated with 1 and 2 mM L-cysteine, respectively (Fig. 2) .
Compared with untreated cells, pyruvate concentrations were dramatically decreased by 0.46 and 0.24 times in cells treated with 1 and 2 mM L-cysteine, respectively (Fig. 2) . In addition, L-cysteine treatment resulted in reduced concentrations of the metabolites in the TCA cycle that were downstream metabolites of pyruvate, including citrate, cis-aconitate, isocitrate, α-ketoglutarate, succinate, fumarate, and malate (11) (Fig. 2) . In contrast, there were almost no alterations in the levels of upstream pyruvate metabolites, such as glucose 6-phosphate, fructose 6-phosphate, fructose 1,6-bisphosphate, glyceraldehyde 3-phosphate, 3-phosphoglycerate, 2-phosphoglycerate, and PEP (9) (Fig. 2) . These results indicated that L-cysteine treatment attenuated glucose-mediated production of pyruvate and its downstream metabolites.
Indeed, L-cysteine treatment resulted in reduced NADH and NAD + levels, which are downstream pyruvate metabolites and positive regulators of GSIS first phase (11, 29) , to ∼0.6-0.9 times of those in untreated cells, and that of malonyl-CoA, which is a downstream pyruvate metabolite and a positive regulator of GSIS second phase (11, 30) , to ∼40% of that in untreated cells (Fig. 2) . Unlike the L-cysteine-induced inhibition of glucoseinduced ATP production shown in Fig. 1B , ATP concentrations in L-cysteine-treated cells were indistinguishable from those in untreated cells, which indicated that L-cysteine treatment had specifically inhibited glucose-stimulated ATP production but had little effect on steady-state ATP levels. In fact, we also examined the effect of L-cysteine on the oxygen consumption rate, which is correlated with the activation of the TCA cycle, and found that glucose-stimulated oxygen consumption was inhibited by L-cysteine (Fig. S2C ).
Inhibitory Effect of L-Cysteine on GSIS Is Rescued by Methyl Pyruvate.
Our comprehensive metabolic analysis of L-cysteine-treated cells showed that L-cysteine treatment resulted in reduced amounts of pyruvate and its downstream metabolites without significantly altering the levels of its upstream metabolites (Fig. 2) . It was previously reported that pyruvate and its downstream metabolites were closely involved in GSIS (11) . Thus, we first investigated the effects of methyl pyruvate, a membrane-permeable form of pyruvate that is used to generate these downstream metabolites, on insulin secretion. After incubating MIN6 cells in 25G-M that contained 2 mM L-cysteine for 24 h, the cells were preincubated with 3G-KRBB that contained 2 mM L-cysteine for 1 h, and were then used for GSIS assays using 25G-KRBB that contained either 2 mM L-cysteine or a 2-mM L-cysteine/2-mM methyl pyruvate mixture for 30 min. As shown in Fig. S3A , 2 mM methyl pyruvate significantly restored the GSIS response of MIN6 cells under static incubation, even in the presence of 2 mM L-cysteine. We also found that methyl pyruvate alone induced insulin secretion to the same level as 25 mM glucose ( Fig. S3B ) and that insulin secretion was induced by methyl pyruvate even in the presence of 1 or 2 mM L-cysteine (Fig. S3C) . These results suggested that L-cysteine attenuated insulin secretion by the inhibition of pyruvate production, which was restored by the addition of methyl pyruvate.
Next, to more closely investigate the kinetics of GSIS, we assessed the effects of methyl pyruvate on GSIS by L-cysteinetreated MIN6 cells using perifusion systems (Materials and Methods and Table S2 ). Fig. S3D shows the effects of L-cysteine on GSIS by MIN6 cells that were perifused with 12 mM glucosecontaining KRBB (12G-KRBB) in the presence or absence of 2 mM L-cysteine. Using 12G-KRBB without L-cysteine, typical GSIS was observed (Fig. S3D) ; high-glucose caused a rapid, marked increase in insulin secretion within 5-6 min and then declined to basal levels after 10-12 min, after which the first phase was followed by a sustained, lower level second phase of secretion. In contrast, using 12G-KRBB that contained 2 mM L-cysteine, both the first and second phases of insulin secretion were nearly completely inhibited (Fig. S3D) .
When using 12G-KRBB that contained 2 mM L-cysteine and 1.5 mM methyl pyruvate, the GSIS first-phase peak, which was completely inhibited by 2 mM L-cysteine, was restored to the control level (Fig. S3E) , and the second-phase secretion was restored to that of the control (Fig. S3E ).
L-Cysteine Reversibly Inhibits Pyruvate Kinase Activity, GlucoseInduced ATP Production, and GSIS in Insulin-Secreting Cells. Because pyruvate levels were reduced in L-cysteine-treated cells, we examined the effects of prolonged L-cysteine treatment on pyruvate kinase activity, which catalyzes the glycolytic conversion of PEP to pyruvate, in MIN6 cells using an in vitro colorimetric assay (31) (Materials and Methods). As shown in Fig. 3A , lysates prepared from L-cysteine-treated cells had significantly reduced activities by ∼75% and to ∼50% after treatment with 1 mM and 2 mM L-cysteine, respectively. This inhibitory effect of L-cysteine on pyruvate kinase seemed to be reversible.
After incubating MIN6 cells in 25G-M that contained 1 or 2 mM L-cysteine for 24 h, these cells were preincubated with 3G-KRBB without L-cysteine for 1 h and then used for GSIS assays using 25G-KRBB without L-cysteine. After incubation for 30 min, cell lysates were prepared, and pyruvate kinase activity was determined. As shown in Fig. 3A , pyruvate kinase activity in lysates was restored to the original level after 1.5 h of incubation in 3G-KRBB (for 1 h) and 25G-KRBB (for 30 min) without L-cysteine (preparation of MIN6 cell lysates under these different conditions is described in Table S1 ). Using these same conditions, glucose-induced ATP production was also restored after Fig. 3 . L-cysteine treatment reversibly inhibits pyruvate kinase activity, glucose-induced ATP production, and insulin secretion. (A) L-cysteine treatment effects on pyruvate kinase activity. Except for remove samples, MIN6 cells were incubated with 25G-M, 3G-KRBB, and 25G-KRBB supplemented with 0, 1, or 2 mM L-cysteine. For remove samples, MIN6 cells were incubated with 25G-M supplemented with 1 or 2 mM L-cysteine and then 3G-KRBB and 25G-KRBB without L-cysteine. Pyruvate kinase activity levels in control cells were set to 1 (n = 3 each). (B) L-cysteine treatment effects on glucose-induced ATP production. MIN6 cells were incubated under the same conditions as in A. ATP levels were determined at 0 (no stimulation) and at 5 and 30 min after stimulation. ATP levels in nonstimulated cells were set to 1. Samples incubated without L-cysteine were used as a control (n = 6 each). (C) L-cysteine treatment effects on total insulin secretion from MIN6 cells. Except for remove samples, MIN6 cells were incubated with 25G-M and 3G-KRBB supplemented with 0, 1, or 2 mM L-cysteine and then stimulated with 3G-KRBB, 25G-KRBB supplemented with 0, 1, or 2 mM L-cysteine. For remove samples, MIN6 cells were incubated with 25G-M supplemented with 1 or 2 mM L-cysteine and 3G-KRBB, and then stimulated with 25G-KRBB without L-cysteine (n = 6 each). (D-G) L-cysteine treatment effects on first-and second-phase insulin secretion from MIN6 cells (D and E) or from mouse pancreatic islets (F and G). Except for remove samples, cells or islets were incubated with medium and 3G-KRBB supplemented with or without L-cysteine (2 mM for MIN6, 1 mM for islets) and then perifused with 3G-KRBB and 12G-KRBB supplemented with 0 (Control, solid line with ○ in D and F and dotted line in E and G; the lines are identical in D and E, or F and G), 2, or 1 mM L-cysteine (+L-cys, solid line with • in D and F). For remove samples, cells or islets were incubated with medium supplemented with L-cysteine and 3G-KRBB and then perifused with 3G-KRBB and 12G-KRBB without L-cysteine [+L-cys (remove), solid line with □ in E and G] (n = 5-6). The 12G-KRBB was added at 0 min in D-G (see Table S2 for experimental details). Results in B and C were corrected for protein levels (see Table S1 for experimental details). Results are means ± SEs of the means. NS P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001. L-cysteine treatment (Fig. 3B) . Increases in ATP levels after highglucose stimulation were confirmed using "remove" samples, which were equal to the original levels.
Because the main pyruvate kinases in insulin-secreting cells are reported to be PKM1 and PKM2 (32), we first confirmed whether PKM1 and PKM2 were dominant pyruvate kinases in MIN6 cells by immunodepletion and Western blot analysis ( Fig.  S4 A and B) . As shown in Fig. S4B , anti-pyruvate kinase antibody mostly reacted with PKM1 and PKM2 proteins in the MIN6 lysate. Next, we used Western blot analysis with antibodies against PKM1 and PKM2 (Fig. S4 C-E) ; this analysis showed that the protein levels of PKM1 and PKM2 remained essentially the same under all tested conditions (control, L-cys, and remove). These results indicated that L-cysteine treatment had no effect on the protein levels of PKM1 and PKM2 (Fig. S4 C-E) . As expected, GSIS under these same conditions (Fig. 3 A  and B) was also restored in conjunction with restoring pyruvate kinase activity and glucose-induced ATP production by L-cysteine removal. Fig. 3 C-G shows the restoration of GSIS by statically incubated MIN6 cells (Fig. 3C) , perifused MIN6 cells (Fig.  3 D and E and Fig. S5 ), and perifused mouse pancreatic islets (Fig. 3 F and G) after removing L-cysteine. The GSIS kinetics in perifusion experiments showed that removing L-cysteine completely and rapidly restored both the GSIS first and second phase to their control levels.
Collectively, these results suggested that L-cysteine treatment induced a reversible attenuation of pyruvate kinase activity in insulin-secreting cells without affecting the amounts of pyruvate kinase proteins and resulted in reversibly inhibiting glucoseinduced ATP production and GSIS.
Attenuated PKM2 Activity by L-Cysteine Inhibits Glucose-Induced ATP Production and Subsequent GSIS. As shown in Fig. 3 , the reversible inhibition of pyruvate kinase activity, glucose-induced ATP production, and GSIS due to L-cysteine suggested that pyruvate production was crucial for normal glucose-induced ATP production and subsequent GSIS. PKM1 and/or its splicing variant PKM2 are the most abundant glycolytic enzymes in MIN6 cells (Fig. S4B) . To determine whether PKM1 or PKM2 was specifically involved in GSIS by MIN6 cells, we investigated GSIS by statically incubated MIN6 cells in which PKM1 or PKM2 was silenced by siRNA. PKM1-and PKM2-knockdown MIN6 cells were prepared (Materials and Methods and Fig. S6 A and B) , and the extent of GSIS by these knockdown MIN6 cells for 30 min was determined and compared with that of control cells treated with scrambled siRNA. This result showed that GSIS by PKM1-knockdown cells was the same as that of control cells under highglucose stimulation (Fig. S6C) . In contrast, GSIS by PKM2-knockdown cells was inhibited similar to that of control cells under no-glucose stimulation (Fig. 4A and Fig. S6D ). This impaired insulin secretion by PKM2-knockdown cells was restored by adding methyl pyruvate (Fig. S6D) . In addition, in PKM2-knockdown cells, L-cysteine treatment had little effect on GSIS (Fig. 4A) . These results indicated that PKM2, but not PKM1, played a significant role in the regulation of GSIS by L-cysteine treatment in MIN6 cells. For these experiments, siRNA designed for PKM2 and commercial siRNA for PKM1 were used, and the specific isoform silencing of these probes was examined (Fig. S6  A and B) . We confirmed the specific silencing of PKM1 and PKM2 without affecting the PKM2 and PKM1 expression levels.
Using the same conditions as in Fig. 4A , we also examined ATP production by PKM2-knockdown cells after stimulation with high glucose. After high-glucose stimulation of control cells (scramble siRNA-treated cells), there was a transient increase in ATP levels of ∼130% of nonstimulated levels at both 5 and 30 min after stimulation (Fig. 4B, Scramble) . In contrast, in PKM2-knockdown cells, the transient increase in ATP was completely inhibited (Fig. 4B, PKM2 KD) , which suggested that inactivation of PKM2 enzymatic activity by L-cysteine treatment might have inhibited GSIS by impairing glucose-induced ATP production in MIN6 cells.
To confirm the specific role of PKM2 in GSIS or glucoseinduced ATP production in MIN6 cells, we assessed the effects of L-cysteine on the enzymatic activity of mouse PKM2, a commercially available recombinant protein, using an in vitro colorimetric assay (Fig. S7A) . PKM2 activity was inhibited in a dose-dependent manner, and >10 μM L-cysteine was sufficient to show an inhibitory effect in vitro (Fig. S7A) . By comparison, L-cysteine had no inhibitory effect on the activity of a recombinant PKM1 protein in vitro (Fig. S7B) . For the latter, we used a human PKM1 rather than mouse PKM1 because both mouse and human PKM1 were 98% homologous in their amino acid sequences (Fig. S8 ). In addition, we determined the half-maximal inhibition concentration (IC 50 ) of L-cysteine for PKM2 kinase Results in A and B were corrected for protein levels (see Table S1 for experimental details). Results are means ± SEs of the means.
activity. Recombinant PKM2 protein was incubated for 20 min with pyruvate kinase reaction mix in the presence of 0, 1, 10, 50, 100, 1,000, or 10,000 μM L-cysteine, and then its kinase activity was measured with a pyruvate kinase activity assay kit. As shown in Fig. 4C , we determined that the IC 50 of L-cysteine was 59 μM. Furthermore, we constructed a Michaelis-Menten plot and a Lineweaver-Burk plot of PKM2 activity ( Fig. 4D and Fig. S7C , respectively) and determined that the maximum velocity (V max ) or the Michaelis constant (K m ) without L-cysteine was 180 pmol/min or 3.9 mM, respectively. In addition, L-cysteine lowered V max (84 pmol/min) with little effect on K m (4.5 mM). These results indicate that L-cysteine suppresses PKM2 enzymatic activity by noncompetitive inhibition and strongly support our conclusion that L-cysteine inhibits PKM2 activity through the dissociation of PKM2 tetramers.
The PKM2 Activator DASA-10 Restores L-Cysteine-Induced Inhibition of Glucose-Induced ATP Production and Subsequent GSIS. To strengthen the evidence for our hypothesis that PKM2 was a pivotal enzyme for insulin secretion in MIN6 cells, we examined whether PKM2 activation restored the L-cysteine-induced impairments in glucoseinduced ATP production and GSIS. To test this hypothesis, we assessed the effects of DASA-10, a specific activator of PKM2, for restoring glucose-induced ATP production and GSIS in L-cysteine-treated cells. After the cells were precultured in 25G-M that contained 0 or 2 mM L-cysteine for 24 h, these cells were preincubated with 3G-KRBB that contained either DMSO only, 2 mM L-cysteine/DMSO, or 2 mM L-cysteine/20 μM DASA-10 for 1 h, and were then used for GSIS and ATP assays using 25G-KRBB that contained the same concentrations of reagents as for preincubation to initiate GSIS. As shown in Fig. 5A , glucose-induced ATP production was completely inhibited with 25G-KRBB that contained 2 mM L-cysteine/DMSO whereas ATP production was normal when using 25G-KRBB that contained DMSO or 2 mM L-cysteine/20 μM DASA-10; upon glucose stimulation, ATP levels increased to almost 210% of nonstimulated levels at 5 min after stimulation, and to 200% or 180% at 30 min, respectively (Fig. 5A) . These results suggested that PKM2 enzymatic activity, which was activated by adding DASA-10 to L-cysteinetreated cells, could ameliorate the L-cysteine-induced impairment in glucose-induced ATP production. As expected, under the same conditions, L-cysteine-induced impairment of GSIS by MIN6 cells under static incubation was also restored by DASA-10 treatment (Fig. 5B) . Next, we investigated the effects of DASA-10 on GSIS by L-cysteine-treated MIN6 cells and mouse pancreatic islets using perifusion systems. After MIN6 cells were precultured in 25G-M that contained 2 mM L-cysteine for 24 h, these cells were preincubated and perifused with 3G-KRBB that contained 2 mM L-cysteine/DMSO or 2 mM L-cysteine/5 μM DASA-10 for 30 min, and then GSIS by perifused MIN6 cells was assessed using 12G-KRBB in the presence of either DMSO only, 2 mM L-cysteine/ DMSO, or 2 mM L-cysteine/5 μM DASA-10. When 12G-KRBB that contained 2 mM L-cysteine/DMSO was used, typical GSIS was completely inhibited (Fig. 5C , "+L-cys"). In contrast, as shown in Fig. 5D , DASA-10 treatment restored GSIS first and second phases to their control levels, as was also shown when using 12G-KRBB without L-cysteine. L-cysteine-mediated inhibition of GSIS and its restoration by DASA-10 were also observed in mouse pancreatic islets ( Fig. 5 E and F) .
Collectively, these results indicated that prolonged L-cysteine treatment might have caused inactivation of PKM2 enzymatic activity both in MIN6 cells and in mouse pancreatic islets and resulted in impaired glucose-induced ATP production and subsequent GSIS. Table S2 for experimental details). (G) L-cysteine or DASA-10 treatment effects on PKM2 tetramer formation in vitro and in MIN6 cells. MIN6 cell lysates or recombinant mouse PKM2 proteins were added to DMSO only, DMSO/1 mM L-cysteine, or 10 μM DASA-10/1 mM L-cysteine and then incubated. After incubation, PKM2 tetramer, dimer, and monomer forms were separated by native SDS/PAGE and immunoblotted with an anti-PKM2 antibody. Results in A and B were corrected for protein levels. For assays that included DASA-10, we used the same amount of DMSO as a negative control (see Tables S1 and S2 for experimental details).
Results are means ± SEs of the means. NS P > 0.05, **P < 0.01, ***P < 0.001.
and found that DASA-10 was sufficient to rescue the L-cysteine (1 mM)-induced impairment of mouse recombinant PKM2 protein enzymatic activity in a dose-dependent manner using an in vitro colorimetric assay (Fig. S7D) . PKM2 subunit dissociation (tetramers to dimers/monomers) results in downregulating its activity (33) (34) (35) . Thus, we investigated the effect of L-cysteine and DASA-10 treatment on the oligomerization states of PKM2 protein in MIN6 cells using native SDS polyacrylamide gel electrophoresis (SDS/PAGE) based on the method of Nowakowski, et al. (36) . As shown in Fig. 5G , three PKM2 states, monomer, dimer, and tetramer, were readily recognizable on native SDS/PAGE. The tetramer form, which is known to be an active form of PKM2, eventually disappeared in L-cysteine-treated cells compared with untreated cells (Fig. 5G) . In contrast, when cells were incubated with L-cysteine in the presence of 10 μM DASA-10, tetramer formation was observed even in the presence of 1 mM L-cysteine (Fig. 5G) . We also investigated the PKM1 state in L-cysteine-treated MIN6 cells and found that L-cysteine or DASA-10 showed no effect on the tetramer-dimer-monomer ratio of PKM1 (Fig. S7E) .
In addition, we performed an in vitro assay using recombinant PKM2 and PKM1 to determine whether L-cysteine directly inhibited the tetramer formation. Recombinant PKM2 or PKM1 protein was incubated with DMSO, DMSO/1 mM L-cysteine, or 10 μM DASA-10/1 mM L-cysteine for 1 h and then was subjected to native SDS/PAGE and Western blotting using antibodies against PKM2 or PKM1. We found that L-cysteine induced the dissociation of PKM2 tetramer in vitro and that it was restored by DASA-10 (Fig. 5G) . We detected the time delay of 20 min before the reactivation of PKM2 enzymatic activity by DASA-10 ( Fig. S7D) , which might be required for the interaction between PKM2 and DASA-10 and the subsequent tetramer formation to fully activate PKM2 activity. In contrast, no significant change was observed in the tetramer-dimer-monomer equilibrium of PKM1 with L-cysteine or DASA-10 (Fig. S7E) . These results strongly suggest that L-cysteine directly inhibited the tetramer formation of PKM2, leading to the specific inhibition of enzymatic activity of PKM2, but not of PKM1.
Taken together, these data suggested that L-cysteine directly impaired PKM2 activity (Fig. 5G and Fig. S7A ) and that PKM2 activity in L-cysteine-treated MIN6 cells might have been downregulated (by subunit dissociation) in a reversible manner to inhibit the glycolytic pathway toward pyruvate production.
Discussion
Pyruvate kinase (EC 2.7.1.40) has four identified isoforms; L, R, M1, and M2 (31) . PKM2 is expressed in embryonic, fetal, adult dividing (e.g., adipocytes, lung, pancreatic islet, and spleen), and tumor cells (22, 31, 37, 38) and plays a crucial role in catalyzing the transphosphorylation from PEP to pyruvate as the rate-limiting step of glycolysis for ATP production. PKM2 also has many nonglycolytic functions. For example, nuclear PKM2 has protein kinase activity and phosphorylates tyrosine residues using PEP as a phosphate donor, which plays a role in promoting cell proliferation (34) . PKM2 is also a phosphotyrosine-binding protein, and the phosphotyrosine-binding form of PKM2 is a critical factor for the rapid growth of cancer cells (39) . In addition, EGFR-induced protein interactions between ERK2 and PKM2 result in PKM2 nuclear translocation, which functions as a coactivator for gene transcription and promotes the Warburg effect, during which aerobic glycolysis rather than mitochondrial oxidative phosphorylation is enhanced to produce energy in cancer cells (40) . Pyruvate kinase activity of PKM2 is optimal when it forms tetramers and is down-regulated by subunit dissociation into dimers or monomers (33) (34) (35) whereas the dimeric form is a protein kinase (34) . These reports indicated that the multifunctional enzymatic activity of PKM2 depended not only on its expression level but also on the allosteric regulation between tetramers, dimers, and monomers.
In this study, we found that L-cysteine inhibited pyruvate kinase activity of PKM2 due to L-cysteine-induced dissociation of PKM2 tetramers to dimers/monomers in vitro and in insulinsecreting cells (Fig. 5G) , inhibited the transient but crucial increase in intracellular ATP levels upon high-glucose stimulation, and resulted in serious defects in GSIS by insulin-secreting cells (Fig. 5) . The proposed mechanisms are summarized in Fig. 6 .
It has been shown that the amount of intracellular pyruvate, which is produced from PEP by pyruvate kinase, plays a crucial role in GSIS (11) . However, the precise role of pyruvate in the L-cysteine-induced inhibition of GSIS has remained unclear because the amounts of pyruvate in cells cannot be determined unambiguously. L-cysteine is one of the inhibitors of pyruvate kinase and is also a substrate for cystathionine γ-lyase (CSE) for generating pyruvate (41) (42) (43) . Our comprehensive analysis of the metabolites in L-cysteine-treated cells showed that the amount of pyruvate in these cells eventually decreased compared with control cells, probably because demand may have overtaken supply (Fig. 2) . In addition, defective GSIS induced by L-cysteine was restored by exogenously added methyl pyruvate (Fig. S3 A and E) or by PKM2 activation with DASA-10 ( Fig. 5 B, D, and  F) . This result suggested that L-cysteine had induced seriously defective GSIS, in which both the first and second phases of insulin secretion had been abolished in insulin-secreting cells due to the decreased levels of pyruvate and production of its downstream metabolites.
The impaired PKM2 activity by L-cysteine was likely attributable to the direct interaction between L-cysteine and PKM2. As shown in Fig. S7A , the enzymatic activity of a recombinant PKM2 protein in vitro was inhibited in the presence of L-cysteine in a concentration-dependent manner. Furthermore, in vitro or in MIN6 cells, L-cysteine induced the dissociation of PKM2 tetramers (active form) to dimers/monomers (inactive forms), which resulted in decreased PKM2 enzymatic activity for pyruvate production (Fig. 5G) . We also found that L-cysteine had no effect on the equilibrium between tetramer and dimer/monomer of the PKM1 protein either in vitro or in MIN6 cells (Fig. S7E) . These results strongly suggested that L-cysteine specifically inhibits PKM2 enzymatic activity in MIN6 cells by directly regulating the equilibrium between the tetramer and the dimer/ monomer through noncompetitive inhibition. Although the precise mechanism of tetramer dissociation by L-cysteine remains unclear, one possible mechanism is that L-cysteine might affect the major . Model for glucose-stimulated insulin secretion (GSIS) inhibition due to increased L-cysteine concentrations in the extracellular environment. Increased L-cysteine concentrations in the extracellular environment are associated with increased intracellular levels, which induce PKM2 inactivation by disrupting PKM2 tetramer formation (pyruvate kinase active form) due to increased direct binding of L-cysteine to PKM2. PKM2 inactivation results in inhibiting glucose-induced ATP production and insulin secretion. Thus, reduced L-cysteine concentrations in the extracellular environment readily restore glucose-induced ATP production and insulin secretion to normal levels.
intersubunit contact domain, which was anticipated from the model resulting from X-ray crystallographic analyses (44) . Based on this 3D structural analysis, an alternate possibility is that L-cysteine is substituted for L-serine, which binds to PKM2 to activate it (44), and results in impaired PKM2 activity through either attenuation of its tetramer dissociation or direct structural PKM2 modifications. Further studies are needed to clarify the role of L-cysteine in impaired PKM2 activity.
Perifusion analysis of GSIS by MIN6 cells and mouse pancreatic islets revealed that both the first and second phases were inhibited by L-cysteine treatment (Figs. 3 D and F Figs. S3D and S5A ). To our knowledge, this report is the first to show a negative L-cysteine effect on the first phase of insulin release that is commonly recognized as the early phenotype found in impaired glucose tolerance, which is closely associated with further progression to T2D (45) (46) (47) . To inhibit first-phase secretion, it is quite possible that L-cysteine primarily inhibits glucose-induced ATP production. As shown in Fig. 2 , the decrease in pyruvate levels in L-cysteine-treated cells depressed the TCA cycle and resulted in a reduced NADH supply from the TCA cycle, which subsequently inhibited transient ATP production upon high-glucose treatment. Although H 2 S production from L-cysteine was shown to limit GSIS by impairing K ATP channels and VDCCs (18) (19) (20) , this effect could be ruled out because adding methyl pyruvate and DASA-10 restored GSIS by L-cysteine-treated cells (Fig. 5 and Fig. S3 ). In fact, we detected no increase in H 2 S concentration in MIN6 cells by prolonged treatment with L-cysteine (Fig. S2B) . The reason why the prolonged L-cysteine treatment in our study had no effect on H 2 S production in MIN6 cells, in contrast to the transient L-cysteine treatment in (15) , remains unclear, and further studies will be needed for clarifying the reason. We speculate that the inconsistency is due to the difference between the prolonged and transient treatments with L-cysteine. The degradation of H 2 S may be enhanced by the activities of catalytic enzymes during the prolonged (∼24 h) treatment of MIN6 cells.
The necessity of the prolonged treatment of L-cysteine for inhibiting insulin secretion may be due simply to the slowness of L-cysteine uptake (or accumulation) in MIN6 cells. As shown in Fig. 3 , the accumulated L-cysteine in MIN6 cells seems to be metabolized or to flow readily out of cells, at least within 90 min of incubation with 3G-KRBB and 25G-KRBB without L-cysteine. So it will take a long time to accumulate a sufficient amount of L-cysteine in MIN6 cells for the inhibition of PKM2 activity.
The precise reason why second-phase insulin secretion was inhibited in L-cysteine-treated cells remains unclear. One possible mechanism is that decreased amounts of malonyl-CoA due to a shortage of pyruvate in L-cysteine-treated cells resulted in reduced concentrations of long-chain acyl-CoA, which was predicted to be necessary for activating the GSIS second phase due to the inhibition of carnitine palmitoyl transferase by malonylCoA (30) . However, opposite results have also been reported: i.e., malonyl-CoA and long-chain acyl-CoA had no effects on GSIS (48, 49) . Furthermore, we could not rule out that other metabolites in L-cysteine-treated cells might affect GSIS. For example, oxaloacetate, which is a TCA-cycle metabolite, was suggested to inhibit serine/threonine protein phosphatase resulting in activation of GSIS (50) . In addition, previous reports demonstrated that decreased oxaloacetate production from pyruvate by inactivation of pyruvate carboxylase attenuated GSIS first and second phases (11, 24) . Although the amounts of oxaloacetate were not determined in this analysis (Fig. 2) , other TCA-cycle metabolites were found to be decreased and might have had an effect on GSIS through a metabolic amplifying pathway, another insulin secretion pathway (Fig. 2) . Thus, the L-cysteine effects on inhibiting second-phase secretion will require further experimental validation.
One of our interesting findings was that L-cysteine-induced inhibition of GSIS in insulin-secreting cells was reversible, at least under our experimental conditions (Fig. 3 C-G and Fig. S5 ). Although there have been many reports that showed that L-cysteine had an inhibitory effect on GSIS, to our knowledge, our results are the first to show a reversible L-cysteine effect on GSIS. This reversibility aspect will be important for elucidating the physiological role of L-cysteine in blood. As shown in Fig. 3 C-G and Fig. S5 , even after prolonged exposure to 1-2 mM L-cysteine by MIN6 cells and mouse pancreatic islets, preincubation for 1 h without L-cysteine followed by stimulation with high glucose for 30 min was sufficient for these cells to have restored normal GSIS, which showed that this L-cysteineinduced inhibition was reversible. This result indicates that an increased L-cysteine concentration in the blood not only can be one possible cause of impaired insulin secretion from islet cells but also is possibly involved in homeostatic regulation to prevent excessive insulin secretion.
Increased L-cysteine in the blood is a reported biomarker of obstructive sleep apnea, which is an independent risk factor for diabetes (6, 7) . In addition, an increase in the total free cysteine concentration in blood of more than twofold was associated with an increase in body mass (1), which is another risk factor for diabetes (3) . Furthermore, improved drugs for diabetes control, such as bis(ethylmal-tolato)oxovanadium(IV) (BEOV) and bis (maltolato)oxovanadium(IV) (BMOV), decreased blood concentrations of L-cysteine in Zucker rats, a well-known obesity model animal (51) . These reports support that exposure to high concentrations of L-cysteine by islet cells is one of the crucial regulatory factors for GSIS and that ameliorating these high blood concentrations of L-cysteine might be a therapeutic modality for diabetes.
Our results suggest that exposure to elevated L-cysteine levels by pancreatic β-cells can cause a significant perturbation of biphasic insulin secretion and ATP production upon high-glucose stimulation due to the impaired glycolytic enzyme activity of PKM2 accompanying the subunit dissociation of tetramer form, probably by a direct interaction between L-cysteine and PKM2. Moreover, removing L-cysteine or treating it with a PKM2 activator restores PKM2 activity, ATP production, and insulin secretion, thus proposing that these inhibitions are reversible. Because PKM2 has received much attention recently as a biomarker for various cancers (52, 53) , the PKM2 regulatory mechanism of L-cysteine suggests a potential therapeutic target for both T2D and cancer.
Materials and Methods
Cell Culture. MIN6 cells were a kind gift from Jun-ichi Miyazaki (Osaka University, Osaka, Japan). MIN6 cells were cultured in DMEM that contained 25 mM glucose (Wako) supplemented with 10% (vol/vol) FCS (GIBCO), penicillin/streptomycin (GIBCO), and 72 μM β-mercaptoethanol (Wako) (hereafter, 25G-M) in humidified 5% CO 2 at 37°C. Table S1 and Table S2 for detailed experimental conditions and procedures.
MIN6 Cells Precultured in
Isolation and Culture of Mouse Pancreatic Islets. Pancreatic islets were isolated from male C57BL/6J mice (CLEA) aged 8 wk by the collagenase digestion method as described previously (54) . The animal care and experimental procedures were approved by the Animal Care Committee of the University of Tokyo. Groups of 20 size-matched islets were handpicked and precultured in RPMI 1640 that contained 11 mM glucose (Nissui) supplemented with 10% (vol/vol) FCS and penicillin/streptomycin with 0 or 1 mM L-cysteine for 24 h in humidified 5% CO 2 at 37°C, before being used for the insulin secretion assay. See Table S2 for the detailed experimental conditions and procedures.
Antibodies and Reagents. We used the following primary antibodies: rabbit anti-actin antibody (A5060; Sigma-Aldrich), rabbit anti-PKM1-specific antibody (15821-1-AP; Proteintech), rabbit anti-PKM2-specific antibody (15822-1-AP; Proteintech), rabbit anti-pyruvate kinase antibody (AV41699; Sigma-Aldrich), mouse anti-β-tubulin antibody (T8328; Sigma-Aldrich), and mouse anti-proinsulin/insulin antibody (L6B10; Cell Signaling). The following secondary antibodies were used: HRP-conjugated anti-mouse IgG antibody (W4021; Promega) and HRP-conjugated anti-rabbit IgG antibody (7074; Cell Signaling). The following reagents were also used: L-cysteine (Wako), DASA-10 (Millipore), methyl pyruvate (Sigma Aldrich), and maitotoxin (Wako).
RNA Interference. Small interfering RNAs (siRNAs) directed against mouse PKM1 or PKM2 were from Sigma-Aldrich. These siRNAs were designed to specifically knockdown a PKM1 or a PKM2 splicing variant of the mouse PKM gene using the Rosetta siRNA Design Algorithm (Sigma-Aldrich). The siRNA sequences were as follows: PKM2 siRNA, 5′-GUGCGAGCCUCCAGUCACUdTdT-3′; and PKM1 siRNA, 5′-GGCAGAGGCUGCCAUCUACdTdT-3′. Scrambled siRNA was from Ambion. A total of 1.8 × 10 5 MIN6 cells were transfected with 100 pmol of siRNA using Lipofectamine RNAi Max (Invitrogen) according to the manufacturer's instructions. After incubation for 48 h, the cells were used for insulin secretion, ATP production, and immunoblotting assays. When RNA interference was combined with L-cysteine treatment, L-cysteine was added to culture medium after 24 h of siRNA transfection.
In Vitro Pyruvate Kinase Activity Assay. Human PKM1 or mouse PKM2 protein was purchased from Sigma or from Abcam, respectively. PKM1 and PKM2 enzymatic activity and half-maximal inhibition concentration (IC 50 ) of L-cysteine were determined using pyruvate kinase activity assay kits (Biovision) according to the manufacturer's instruction. Briefly, 10 ng of PKM2 or 1 ng of PKM1 protein was incubated with pyruvate kinase reaction mix (Biovision) containing different concentrations of L-cysteine (0-10,000 μM) for 20 min (IC 50 ) or 0-90 min (enzymatic activity). After the incubation, pyruvate kinase activity of PKM1 or PKM2 was calculated by measuring pyruvate contents in the mixture.
We determined the maximum velocity (V max ) and the Michaelis constant (K m ) of PKM2 enzymatic activity and the effect of L-cysteine on V max and K m according to the method of Chaneton et al. (44) with slight modifications. Because pyruvate kinase catalyzes the reaction of phosphoenolpyruvate (PEP) + ADP → pyruvate + ATP, its activity could be estimated by the ATP content in the reaction mixture. Recombinant PKM2 protein was incubated with 50 mM Tris, 100 mM KCl, 10 mM MgCl 2 , 200 mM ADP, 3% (vol/vol) DMSO, and 0-10 mM PEP in the presence or absence of 59 μM L-cysteine for 20 min. Then, the ATP content was measured with an ATP determination kit (Molecular Probes) and was normalized to the control without PKM2 proteins. We constructed a Michaelis-Menten plot and a Lineweaver-Burk plot and determined V max and K m .
In Vivo Pyruvate Kinase Activity Assay. After MIN6 cells were washed twice with KRBB (140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH 2 PO 4 , 0.5 mM MgSO 4 , 1.5 mM CaCl 2 , 10 mM Hepes, and 2 mM NaHCO 3 , pH 7.4), these cells were preincubated with 3 mM glucose-containing KRBB (3G-KRBB) supplemented with 0, 1, or 2 mM L-cysteine at 37°C for 1 h and then washed with KRBB. Subsequently, the cells were incubated with 25 mM glucose-containing KRBB (25G-KRBB) supplemented with 0, 1, or 2 mM L-cysteine at 37°C for 30 min. After incubation, the cells were washed twice with ice-cold PBS and lysed with 4 volumes of pyruvate kinase assay buffer (Biovision). Cell lysates were centrifuged at 20,400 × g at 4°C for 5 s, after which supernatants were collected. Pyruvate kinase activity in a supernatant was determined using a pyruvate kinase activity assay kit according to the manufacturer's instructions. Total protein in a supernatant was adjusted to 3 μg. SDS/PAGE and Western Blotting. Native SDS/PAGE was performed using a 5-20% wt/vol acrylamide gradient gel (Wako) and gel running buffer (0.25 M Tris-base and 1.92 M glycine) that contained 0.05% SDS under constant current conditions (20 mA/gel) at 4°C for 180 min, after which proteins were transferred to a polyvinylidene fluoride (PVDF) membrane using the wettank method. Other experiments were performed according to methods described by Nowakowski et al. (36) with slight modifications. SDS/PAGE used a 5-20% wt/vol acrylamide gradient gel and gel running buffer that contained 0.1% SDS under constant current conditions (20 mA/gel) at room temperature for 80 min, after which proteins were transferred to a PVDF membrane using a Trans-Blot SD cell (Bio-Rad). A membrane was blocked with 5% (wt/vol) BSA or 5% (wt/vol) nonfat dry milk in TBST (TBS containing 0.1% Tween 20) at room temperature for 60 min, incubated with appropriate primary antibodies at 4°C overnight and then with HRP-conjugated secondary antibodies at room temperature for 60 min. Antigen-antibody complexes were detected using enhanced chemiluminescence reagents (Western Lightning Plus-ECL; Perkin-Elmer). Band intensities were quantified using an LAS-4000 mini imaging system (GE Healthcare).
Insulin Secretion from Statically Incubated Cells. Under conditions of prolonged L-cysteine treatment, after MIN6 cells were washed twice with KRBB, they were preincubated in 3G-KRBB supplemented with 0, 1, or 2 mM L-cysteine at 37°C for 1 h and then washed with KRBB. Subsequently, the cells were incubated in 3G-KRBB or 25G-KRBB supplemented with 0, 1, or 2 mM L-cysteine at 37°C for 30 min. Under conditions of transient L-cysteine treatment, cells precultured without L-cysteine were washed twice with KRBB, preincubated in 3G-KRBB at 37°C for 1 h, and then washed with KRBB. Subsequently, the cells were incubated in 25G-KRBB supplemented with 0, 1, or 2 mM L-cysteine at 37°C for 30 min. When methyl pyruvate treatment was combined with L-cysteine treatment, 2 mM methyl pyruvate was added to 25G-KRBB for incubation. When DASA-10 treatment was combined with L-cysteine treatment, 20 μM DASA-10 or DMSO was added to 3G-KRBB and 25G-KRBB for preincubation and incubation. After incubation, the buffers used during incubation were collected and centrifuged at 20,400 × g at 4°C for 1 min. Subsequently, insulin in these supernatants was determined using an AlphaLISA insulin kit (PerkinElmer). See Table S1 for detailed experimental conditions and procedures.
Insulin Secretion from Perifused MIN6 Cells and Mouse Pancreatic Islets. MIN6 cells or groups of 20 size-matched mouse pancreatic islets were washed twice with KRBB and preincubated in 3G-KRBB supplemented with 0, 1, or 2 mM L-cysteine at 37°C for 30 min. These cells were then perifused at a rate of 0.5 mL/min (for MIN6 cells) or 50 μL/min (for mouse pancreatic islets) with the same buffer at 37°C for 30 min for equilibration, and the glucose concentration was increased to 12 mM (12 mM glucose-containing KRBB, 12G-KRBB) with or without L-cysteine and then perifused for an additional 30 min. When methyl pyruvate treatment was combined with L-cysteine treatment, 1.5 mM methyl pyruvate was added to 12G-KRBB for the duration of high-glucose stimulation. When DASA-10 treatment was combined with L-cysteine treatment, 5 μM DASA-10 or DMSO was added to 3G-KRBB and 12G-KRBB. During perifusion experiments, effluent buffer was collected at 1-min intervals for insulin measurements. The buffers were centrifuged at 20,400 × g at 4°C for 1 min, after which insulin in supernatants was determined using an AlphaLISA insulin kit. See Table S2 for detailed experimental conditions and procedures.
Quantification of Intracellular ATP Levels. The cells were washed twice with KRBB and lysed with passive lysis buffer (Promega). After two freeze/thaw cycles and centrifugation (20,400 × g, 4°C, 1 min), ATP levels in supernatants were measured using an ATP determination kit (Molecular Probes) according to the manufacturer's instructions.
Analysis of Ionic
Metabolites by CE-TOF-MS. Analysis of ionic metabolites was carried out by Human Metabolome Technologies, Inc. as described previously (55, 56) . Detailed experimental conditions are described in SI Materials and Methods.
Statistical Analysis. For the results shown in Figs. 1 and 3 A-C and Figs. S1 A and B, S2B, S3C, S4 D and E, and S6C, statistical comparisons were made using Dunnett's post hoc test. For results in Fig. 4A and Fig. S3 A and B , statistical comparisons were made using Bartlett's test and Tukey-Kramer or Steel-Dwass test. For results in Fig. 5A and B and Fig. S6D , statistical comparisons were made using F-tests and Student's t tests with Bonferroni corrections. For results in Fig. 4B and Figs. S2C and S6 A and B, statistical comparisons were made using F-tests and Student's t tests. Results are given as means ± SEs of the means (SEMs). Significant differences were considered at *P < 0.05, **P < 0.01, and ***P < 0.001.
